Acute Myeloid Leukemia (AML) is an aggressive cancer of the bone marrow that results from the uncontrolled growth of abnormal hematopoietic stem cell (HSC) populations.   The goal of this project is to characterize the mechanisms for the transformation of genetically engineered human primary HSCs to AML. My aim is to validate FLT3-ITD CRISPR-Cas9 reagents to contribute to the sequential editing matrix scheme of the larger project of investigating preleukemic stem cells as therapeutic targets in AML. Understanding the genetic components of preleukemia can help inform clinical decisions of which patients to provide transplants and in what stage of remission this therapy can be most effective.